$SLRX
Salarius Pharmaceuticals, Inc. Stock $slrx

$slrx Overview Financials Valuation SEC Filings Company Website

2017 Q3 Form 10-Q Financial Statement

#000161521917000067 Filed on August 02, 2017

Income Statement

Concept	2017 Q3	2017 Q2	2016 Q2
Revenue	$413.6K	$335.5K	$112.7K
YoY Change	-30.96%	197.75%
Cost Of Revenue	$148.8K	$145.3K	$110.9K
YoY Change	-32.72%	31.0%
Gross Profit	$264.8K	$190.2K	$1.754K
YoY Change	-29.93%	10743.67%
Gross Profit Margin	64.03%	56.69%	1.56%
Selling, General & Admin	$4.930M	$4.990M	$5.380M
YoY Change	-9.54%	-7.25%	37.95%
% of Gross Profit	1861.47%	2623.58%	306727.48%
Research & Development	$4.739M	$4.076M	$6.095M
YoY Change	-16.34%	-33.12%	91.05%
% of Gross Profit	1789.48%	2143.15%	347486.94%
Depreciation & Amortization	$80.00K	$80.00K	$60.00K
YoY Change	0.0%	33.33%	500.0%
% of Gross Profit	30.21%	42.06%	3420.75%
Operating Expenses	$9.823M	$9.212M	$11.58M
YoY Change	-13.33%	-20.47%	63.27%
Operating Profit	-$9.409M	-$8.877M	-$11.47M
YoY Change	-12.35%	-22.61%	61.69%
Interest Expense	$80.00K	$70.00K	$110.0K
YoY Change	-20.0%	-36.36%	450.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$9.330M	-$8.800M	-$11.47M
YoY Change	-13.09%	-23.28%	61.69%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$9.332M	-$8.805M	-$11.36M
YoY Change	-12.27%	-22.52%	60.53%
Net Earnings / Revenue	-2256.31%	-2624.15%	-10083.98%
Basic Earnings Per Share
Diluted Earnings Per Share	-$13.33M	-$12.75M	-$17.75M
COMMON SHARES
Basic Shares Outstanding	17.97M shares	17.97M shares	17.97M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q3	2017 Q2	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$38.90M	$47.10M	$74.90M
YoY Change	-42.2%	-37.12%	-29.34%
Cash & Equivalents	$20.41M	$39.25M	$38.90M
Short-Term Investments	$18.80M	$8.000M	$35.90M
Other Short-Term Assets	$1.100M	$1.200M	$2.300M
YoY Change	-31.25%	-47.83%	187.5%
Inventory	$534.0K	$688.2K	$274.3K
Prepaid Expenses
Receivables	$35.13K	$34.74K	$11.60K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$40.55M	$49.06M	$77.40M
YoY Change	-41.35%	-36.62%	-27.54%
LONG-TERM ASSETS
Property, Plant & Equipment	$401.0K	$448.1K	$637.1K
YoY Change	-35.26%	-29.66%	435.37%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$0.00
YoY Change
Other Assets	$0.00	$0.00	$64.80K
YoY Change	-100.0%	-100.0%	-23.94%
Total Long-Term Assets	$654.2K	$574.7K	$828.7K
YoY Change	-19.31%	-30.65%	117.43%
TOTAL ASSETS
Total Short-Term Assets	$40.55M	$49.06M	$77.40M
Total Long-Term Assets	$654.2K	$574.7K	$828.7K
Total Assets	$41.21M	$49.63M	$78.23M
YoY Change	-41.09%	-36.56%	-27.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$919.0K	$1.806M	$1.545M
YoY Change	-26.88%	16.93%	90.17%
Accrued Expenses	$3.900M	$3.100M	$1.700M
YoY Change	56.0%	82.35%	41.67%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.973M	$5.033M	$3.397M
YoY Change	27.08%	48.16%	60.73%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$100.0K	$100.0K	$0.00
YoY Change			-100.0%
Total Long-Term Liabilities	$100.0K	$100.0K	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.973M	$5.033M	$3.397M
Total Long-Term Liabilities	$100.0K	$100.0K	$0.00
Total Liabilities	$5.027M	$5.125M	$3.413M
YoY Change	28.11%	50.17%	33.5%
SHAREHOLDERS EQUITY
Retained Earnings	-$103.1M	-$93.72M	-$58.11M
YoY Change	49.9%	61.28%	175.3%
Common Stock	$1.754K	$1.729K	$1.626K
YoY Change	6.17%	6.33%	7.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$36.18M	$44.50M	$74.82M
YoY Change
Total Liabilities & Shareholders Equity	$41.21M	$49.63M	$78.23M
YoY Change	-41.09%	-36.56%	-27.03%

Cashflow Statement

Concept	2017 Q3	2017 Q2	2016 Q2
OPERATING ACTIVITIES
Net Income	-$9.332M	-$8.805M	-$11.36M
YoY Change	-12.27%	-22.52%	60.53%
Depreciation, Depletion And Amortization	$80.00K	$80.00K	$60.00K
YoY Change	0.0%	33.33%	500.0%
Cash From Operating Activities	-$8.050M	-$5.690M	-$9.330M
YoY Change	11.03%	-39.01%	108.72%
INVESTING ACTIVITIES
Capital Expenditures	-$50.00K	-$30.00K	-$180.0K
YoY Change	-77.27%	-83.33%	260.0%
Acquisitions
YoY Change
Other Investing Activities	-$10.75M	$23.78M	-$5.550M
YoY Change	193.72%	-528.47%
Cash From Investing Activities	-$10.79M	$23.74M	-$5.730M
YoY Change	178.09%	-514.31%	11360.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	0.000
YoY Change	-100.0%
NET CHANGE
Cash From Operating Activities	-8.050M	-5.690M	-9.330M
Cash From Investing Activities	-10.79M	23.74M	-5.730M
Cash From Financing Activities	0.000	0.000	0.000
Net Change In Cash	-18.84M	18.05M	-15.06M
YoY Change	69.42%	-219.85%	233.19%
FREE CASH FLOW
Cash From Operating Activities	-$8.050M	-$5.690M	-$9.330M
Capital Expenditures	-$50.00K	-$30.00K	-$180.0K
Free Cash Flow	-$8.000M	-$5.660M	-$9.150M
YoY Change	13.8%	-38.14%	107.01%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Depreciation Depreciation	89958	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001615219
CY2017Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17971816	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Flex Pharma, Inc.
CY2016Q4	flks	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	2587573	USD
CY2017Q2	flks	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	3130394	USD
CY2016Q4	flks	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	938665	USD
CY2017Q2	flks	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	1858526	USD
	flks	Inventory Purchasesin Accounts Payableand Accrued Expense InventoryPurchasesinAccountsPayableandAccruedExpense	0	USD
	flks	Inventory Purchasesin Accounts Payableand Accrued Expense InventoryPurchasesinAccountsPayableandAccruedExpense	441116	USD
	flks	Property And Equipment Purchases In Accrued Expense PropertyAndEquipmentPurchasesInAccruedExpense	106680	USD
	flks	Property And Equipment Purchases In Accrued Expense PropertyAndEquipmentPurchasesInAccruedExpense	7100	USD
	flks	Revenue Recognition Refund Period RevenueRecognitionRefundPeriod	P30D
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1192183	USD
CY2017Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1806359	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12181	USD
CY2017Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	34735	USD
CY2016Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	42024	USD
CY2017Q2	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	507691	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	153219	USD
CY2017Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	208688	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1614	USD
CY2017Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5616	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	135962935	USD
CY2017Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	138227029	USD
CY2016Q2	us-gaap	Advertising Expense AdvertisingExpense	916000	USD
	us-gaap	Advertising Expense AdvertisingExpense	1426000	USD
CY2017Q2	us-gaap	Advertising Expense AdvertisingExpense	1250000	USD
	us-gaap	Advertising Expense AdvertisingExpense	1915000	USD
CY2016Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1988321	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3506482	USD
CY2017Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1073346	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2262098	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4132711	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3354077	shares
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	88344	USD
CY2016Q4	us-gaap	Assets Assets	63214979	USD
CY2017Q2	us-gaap	Assets Assets	49629809	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	62467269	USD
CY2017Q2	us-gaap	Assets Current AssetsCurrent	49055112	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	38658933	USD
CY2017Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	7996199	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2912	USD
CY2017Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	4526	USD
CY2017Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	5616	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	38660547	USD
CY2017Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	8001815	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	16519620	USD
CY2017Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	7996199	USD
CY2016Q4	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	6	security
CY2017Q2	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	3	security
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	161049	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	19630	USD
CY2015Q4	us-gaap	Cash Cash	66686695	USD
CY2016Q2	us-gaap	Cash Cash	38941239	USD
CY2016Q4	us-gaap	Cash Cash	22416040	USD
CY2017Q2	us-gaap	Cash Cash	39126801	USD
CY2017Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	47123000	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-27745456	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	16710761	USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17970590	shares
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17971816	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16773798	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17285926	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	1678	USD
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	1729	USD
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11343248	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20891450	USD
CY2017Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8797886	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17077020	USD
CY2016Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	110931	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	307951	USD
CY2017Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	145325	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	224431	USD
CY2016Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	21095	USD
CY2017Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	0	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	8398	USD
CY2017Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	91878	USD
CY2017Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	96667	USD
	us-gaap	Depreciation Depreciation	171109	USD
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.71
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.31
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.51
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.00
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1453665	USD
CY2017Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	505489	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y4M17D
CY2017Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	7132098	USD
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5377784	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10489479	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4990943	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9585659	USD
CY2016Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	508066	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	601646	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	11595	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	22554	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-78918	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	101705	USD
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	2363	USD
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	62385	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	65115	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	8323	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	274302	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-207063	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	64800	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-64800	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-15442	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1351291	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	283209	USD
CY2016Q2	us-gaap	Interest Income Operating InterestIncomeOperating	107818	USD
	us-gaap	Interest Income Operating InterestIncomeOperating	211151	USD
CY2017Q2	us-gaap	Interest Income Operating InterestIncomeOperating	72342	USD
	us-gaap	Interest Income Operating InterestIncomeOperating	150196	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	454132	USD
CY2017Q2	us-gaap	Inventory Net InventoryNet	688185	USD
CY2016Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	19888	USD
CY2017Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	10441	USD
CY2016Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	434244	USD
CY2017Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	677744	USD
CY2016Q2	us-gaap	Inventory Write Down InventoryWriteDown	40652	USD
	us-gaap	Inventory Write Down InventoryWriteDown	225950	USD
CY2017Q2	us-gaap	Inventory Write Down InventoryWriteDown	17767	USD
	us-gaap	Inventory Write Down InventoryWriteDown	17767	USD
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-78751	USD
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	15895	USD
CY2017Q2	us-gaap	Liabilities Liabilities	5125298	USD
CY2016Q4	us-gaap	Liabilities Liabilities	3897593	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	63214979	USD
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	49629809	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3889195	USD
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5033420	USD
CY2016Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	38658933	USD
CY2017Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7996199	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8043	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2047	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9252292	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	30624261	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18501207	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13915547	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-11363133	USD
	us-gaap	Net Income Loss NetIncomeLoss	-20955594	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-8804623	USD
	us-gaap	Net Income Loss NetIncomeLoss	-17073018	USD
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11363133	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20955594	USD
CY2017Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8804623	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17073018	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	11583636	USD
	us-gaap	Operating Expenses OperatingExpenses	21279430	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	9212488	USD
	us-gaap	Operating Expenses OperatingExpenses	17801284	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-11470951	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21166745	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8876965	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17223214	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	0	USD
CY2017Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	50000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	64800	USD
CY2017Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2016Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	19885	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	64144	USD
CY2017Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	6737	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-4002	USD
CY2016Q2	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	0	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	0	USD
CY2017Q2	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	4835	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	7090	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	22074850	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	9607390	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	290202	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	53741	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	925983	USD
CY2017Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1209192	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	13112760	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	40282017	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	3375	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	8043	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2047	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	556315	USD
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	448102	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6094921	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10482000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4076220	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7991194	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	126595	USD
CY2017Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	126595	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-76645613	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93718631	USD
CY2016Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	112685	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	112685	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	570980	USD
CY2017Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	330688	USD
CY2016Q2	us-gaap	Sales Revenue Net SalesRevenueNet	112685	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	112685	USD
CY2017Q2	us-gaap	Sales Revenue Net SalesRevenueNet	335523	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	578070	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3506482	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2262098	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1226720	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.67
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	279337	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	792500	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1605684	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	939484	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2156250	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2668187	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.66
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.24
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	939484	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2668187	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	7.24
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.67
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	9.81
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.27
CY2017Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	654967	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y10M24D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y11M9D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y11M19D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y11M19D
CY2016Q2	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	28000	USD
	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	28000	USD
CY2017Q2	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	47000	USD
	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	81000	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1226	shares
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	59317386	USD
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	44504511	USD
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16105555	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15974544	shares
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17130264	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17002597	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company outsources the manufacture of HOTSHOT to a single co-packer that produces bottled finished goods. The Company also sources certain raw materials from sole suppliers. A disruption in the supply of materials or the production of finished goods could significantly impact the Company's revenues in the future as alternative sources of raw materials and co-packing may not be available at commercially reasonable rates or within a reasonably short period of time. </font></div></div>
	us-gaap	Revenue Recognition Revenue Reductions RevenueRecognitionRevenueReductions	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Discounts provided to customers are accounted for as a reduction of net product revenue. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"></font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company's management evaluates its estimates, which include, but are not limited to, estimates related to clinical study accruals, estimates related to inventory realizability, stock-based compensation expense and amounts of expenses during the reported period. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001615219-17-000067-index-headers.html	Edgar Link	pending
0001615219-17-000067-index.html	Edgar Link	pending
0001615219-17-000067.txt	Edgar Link	pending
0001615219-17-000067-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
flks-20170630.xml	Edgar Link	completed
flks-20170630.xsd	Edgar Link	pending
flks-20170630_cal.xml	Edgar Link	unprocessable
flks-20170630_def.xml	Edgar Link	unprocessable
flks-20170630_lab.xml	Edgar Link	unprocessable
flks-20170630_pre.xml	Edgar Link	unprocessable
flks201763010-q.htm	Edgar Link	pending
flks2017630ex-311.htm	Edgar Link	pending
flks2017630ex-312.htm	Edgar Link	pending
flks2017630ex-321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SLRX
Salarius Pharmaceuticals, Inc. Stock $slrx

2017 Q3 Form 10-Q Financial Statement

#000161521917000067 Filed on August 02, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLRX Salarius Pharmaceuticals, Inc. Stock $slrx

2017 Q3 Form 10-Q Financial Statement

#000161521917000067 Filed on August 02, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLRX
Salarius Pharmaceuticals, Inc. Stock $slrx